State of Innovation in Antibacterial Therapeutics   [open pdf - 0B]

From the Introduction: "Antibacterial drug discovery and development during the 20th century yielded one of the greatest armaments available to physicians, with more than 90% of all antibacterial drugs discovered during this period. Since the introduction of numerous antibiotic classes during the 1940s, deaths from bacterial infections have been reduced significantly. However, this next century is already presenting challenges that may render these older antibiotics obsolete. The COVID [coronavirus disease 2019] pandemic, which exposed multiple preparedness shortcomings, has elevated attention to the increasing threat of drug-resistant strains of bacteria. More than 1.2 million people worldwide are dying each year from antibiotic resistant infections and it is estimated this number will grow to 10 million per year by 2050. In the U.S. alone, more than 2.8 million antibiotic-resistant infections occur each year, with more than 35,000 people dying as a result. The CDC, EMEA [European Agency for the Evaluation of Medicinal Products], WHO [World Health Organization], IDSA [Infectious Diseases Society of America], Pew, and other groups have issued warnings to public policymakers for more than a decade about the reduced effectiveness of last century's antibiotic arsenal."

Biotechnology Innovation Organization
Retrieved From:
Biotechnology Innovation Organization: https://www.bio.org/
Media Type:
Help with citations